Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer

Li, Ning-chen; Kanda, Kazuya; Fukumori, Tomoharu; Inoue, Yoshio; Nishitani, Masaaki; Kanayama, Hiro‐omi; Kagawa, Shunsuke

doi:10.1016/s1078-1439(00)00095-8

Cited by 22 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the same way, Li et al (44) have detected mRNA expression of four VEGF-A isoforms namely VEGF121, 165, 189 and 206. The levels of VEGF206 and VEGF189 in pT2 tumors were significantly lower than those in pTa and pT1 tumors.…”

Section: Discussionmentioning

confidence: 83%

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Fauconnet¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. The present investigation was conducted first to determine whether correlation exists between VEGF-A and -B mRNA levels and clinicopathological parameters and to assess their prognostic value in bladder cancer, then to clarify the expression level and biological significance of VEGF-A isoforms. Total RNA was isolated from 37 specimens of bladder cancer. Northern blot analysis revealed that VEGF-B mRNA was not expressed either in normal urothelium or in bladder cancer and detected three VEGF-A transcripts of 5.2, 4.5 and 1.7 kb in length, respectively. The VEGF-A transcript levels were greater in cancer tissues than in normal urothelium. They were significantly higher in pT2-T4 than in pTa and pT1 urothelial tumors and thus, were correlated to the pathologic stage. Contrary to the 4.5 kb transcript, elevated expression of the 5.2 and 1.7 kb transcripts was correlated with the histologic grade and the presence of carcinoma in situ. Patients with higher VEGF-A mRNA levels had a significantly shorter survival without progression compared to those with lower levels. Three VEGF-A splice variants were detected by Southern blotting namely, VEGF121, 165 and 189. The expression intensity of each isoform was evaluated by quantitative real-time RT-PCR in 20 new fresh frozen recent tumors. VEGF121 and VEGF165 were expressed at the similar level. On the contrary, they were significantly more expressed than VEGF189 (p<0.05). The three isoforms were higher expressed in pT2 bladder cancers than in pTa tumors (p<0.05). There was only a significant correlation between the increased expression level of VEGF121 and 165 and the histological grade of the lesion (p<0.05). To conclude, VEGF-A mRNA level is a potential prognostic indicator of progression in bladder cancer as well as the expression level of the different VEGF-A splice variants.

show abstract

Section: Discussionmentioning

confidence: 83%

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Fauconnet¹

2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…[13][14][15][16][17]36,37 In addition, the assessment of MVD in a primary tumor ultimately may prove to be a significant and independent prognostic parameter related to tumor recurrence, metastasis, and overall patient survival. [37][38][39][40][41][42] The prognostic significance of angiogenesis has been confirmed in different types of brain tumors, e.g., diffuse astrocytomas of varying grade.…”

Section: Discussionmentioning

confidence: 99%

“…11,12 VEGF is produced in a great variety of cells and is expressed in tumors of many tissues, including lung, breast, stomach, colon, thyroid, kidney, bladder, ovary, and pituitary. [13][14][15][16][17][18][19][20][21] VEGF also has been identified in human craniopharyngiomas, and it has been suggested that cystic foci in these tumors are related to the degree of VEGF expression. 22 To assess directly whether VEGF in craniopharyngiomas is associated with angiogenesis and tumor behavior, we compared the expression pattern of VEGF with both microvessel density (MVD) and clinicopathologic features in 32 adult patients with craniopharyngiomas of both histologic types.…”

mentioning

confidence: 99%

Angiogenesis in patients with craniopharyngiomas

Vidal

Kovács

Lloyd

et al. 2002

Cancer

View full text Add to dashboard Cite

The functional single‐coordinate phosphine oxide ligands (4‐diphenylaminophenyl)diphenylphosphine oxide (TAPO), (4‐naphthalen‐1‐yl‐phenylaminophenyl)diphenylphosphine oxide (NaDAPO), and 9‐[4‐(diphenylphosphinoyl)phenyl]‐9H‐carbazole (CPPO), as the direct combinations of hole‐transporting moieties, and electron‐transporting triphenylphosphine oxide (TPPO) were designed and synthesized (amines or carbazole), together with their EuIII complexes [Eu(tapo)2(tta)3] (1), [Eu(nadapo)2(tta)3] (2), and [Eu(cppo)2(tta)3] (3; TTA: 2‐thenoyltrifluoroacetonate). The investigation indicated that by taking advantage of the modification inertia of the phosphine oxide ligands, the direct introduction of the hole‐transport groups as chromophore made TAPO, NaDAPO, and CPPO obtain the most compact structure and mezzo S1 and T1 energy levels, which improved the intramolecular energy transfer in their EuIII complexes. The amorphous phase of 1–3 proved the weak intermolecular interaction, which resulted in extraordinarily low self‐quenching of the complexes. The excellent double‐carrier transport ability of the ligands was studied with Gaussian calculations, and the bipolar structure of TAPO and CPPO was proved. The great improvement of the double‐carrier transport ability of 1–3 was shown by cyclic voltammetry. Their HOMO and LUMO energy levels of around 5.3 and 3.0 eV, respectively, are the best results for EuIII complexes reported so far. A single‐layer organic light‐emitting diode of 2 had the impressive brightness of 59 cd m−2 which, to the best of our knowledge, is the highest reported so far. Both of the four‐layer devices based on pure 1 and 2 had a maximum brightness of more than 1000 cd m−2, turn‐on voltages lower than 5 V, maximum external quantum yields of more than 3 % and excellent spectral stability.

show abstract

“…[51][52][53] Interestingly, in one study, correlations were observed between tumor grade and the ratio of the various VEGF isoforms, with the levels of VEGF 121 in XpT2 tumors tending to be higher than in ppT1 tumors, whereas the opposite appeared to be the case for VEGF 206 and VEGF 189 . 54 In contrast, studies examining the relationship between overall VEGF expression and tumor progression and long-term patient survival have yielded conflicting results. 55 It has been postulated that differences in the results obtained by different groups reflect, at least in part, the involvement of various post-transcriptional regulatory processes in the control of VEGF expression, resulting in poor agreement between studies in which RNA-and protein-based approaches were used to relate the production of VEGF to clinical outcome.…”

Section: Discussionmentioning

confidence: 99%

“…70 Of particular relevance, a high proportion of bladder tumor cells also appear to express Flk-1 and/or Flt-1. 54,71,72 Thus bladder tumor cells not only produce VEGF but may also show enhanced proliferation and/or migration in response to the cytokine. For example, in one recent study, endogenous VEGF was shown to stimulate proliferation of the Flk-1-positive transitional bladder tumor cell line T24.…”

Section: Discussionmentioning

confidence: 99%

Exploiting the tumor microenvironment in the development of targeted cancer gene therapy

Dougherty

2008

Cancer Gene Ther

View full text Add to dashboard Cite

Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer

Cited by 22 publications

References 23 publications

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Angiogenesis in patients with craniopharyngiomas

Exploiting the tumor microenvironment in the development of targeted cancer gene therapy

Contact Info

Product

Resources

About